Bruce Maluish - Valeant Pharmaceuticals Managing Director, Executive Director
Managing Director
Mr. Bruce Maluish, BSc, Dip Met Min, serves as Managing Director and Executive Director of Ventnor Resources Ltd. He has 30 years experience in the international mining industry and as Managing Director and General Manager with midsize miners such as the Monarch Group of Companies, Matilda Minerals, Abelle, Hill 50 and Forsyth Mining, while mining a variety of commodities such as gold, nickel and mineral sands from both open pits and underground. His management and administrative experience includes the set up and marketing of initial public offering, from commencement of exploration to full production, to the identification, development and expansion of projects including mergers and acquisitions. His international experience includes identification of projects and negotiations with clients in Asian markets. His qualifications include credentials in Surveying, Mining, Project Planning and Finance. He held directorship in Matilda Zircon Ltd and Matilda Minerals Ltd .
| Phone | 514-744-6792 |
| Web | http://www.valeant.com |
Valeant Pharmaceuticals Management Efficiency
The company has Return on Asset of 0.69 % which means that on every $100 spent on assets, it made $0.69 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (21.51) %, meaning that it generated no profit with money invested by stockholders. Valeant Pharmaceuticals' management efficiency ratios could be used to measure how well Valeant Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company has 25.27 B in debt with debt to equity (D/E) ratio of 558.6, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Valeant Pharmaceuticals has a current ratio of 1.16, demonstrating that it may not have the ability to pay its financial commitments when the payables are due. Debt can assist Valeant Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Valeant Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Valeant Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Valeant to invest in growth at high rates of return. When we think about Valeant Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter products, and medical devices. The company was founded in 1983 and is headquartered in Laval, Canada. Valeant Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in USA and traded on New York Stock Exchange. It employs 20700 people. Valeant Pharmaceuticals International (VRX) is traded on New York Stock Exchange in USA and employs 20,700 people. Management Performance
| Return On Equity | -21.51 | |||
| Return On Asset | 0.69 |
Valeant Pharmaceuticals Leadership Team
Elected by the shareholders, the Valeant Pharmaceuticals' board of directors comprises two types of representatives: Valeant Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valeant. The board's role is to monitor Valeant Pharmaceuticals' management team and ensure that shareholders' interests are well served. Valeant Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valeant Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Ingram, Lead Independent Director | ||
| Sarah Kavanagh, Independent Director | ||
| Pavel Mirovsky, President of Valeant Europe and General Manager of Valeant Europe | ||
| William Humphries, Executive Vice President Company Group Chairman, Dermatology | ||
| Bruce Maluish, Managing Director, Executive Director | ||
| Norma Provencio, Independent Director | ||
| Richard DeSchutter, Independent Director | ||
| Anders Lonner, Director | ||
| Robert Hale, Director | ||
| Louis Yu, Chief Quality Officer, Global Quality | ||
| Howard Schiller, Interim CEO and Director | ||
| Paul Herendeen, CFO, Executive Vice President - Finance | ||
| Peter Pawlowitsch, Non-Executive Director | ||
| Amy Wechsler, Independent Director | ||
| Colleen Goggins, Independent Director | ||
| Robert Power, Independent Director | ||
| Mason Morfit, Independent Director | ||
| Sherri Wilkin, Chief Creative Officer | ||
| Robert Rosiello, CFO and Executive VP | ||
| Theo MelasKyriazi, Independent Director | ||
| Argeris Karabelas, Independent Director | ||
| William Ackman, Director | ||
| Fredric Eshelman, Independent Director | ||
| Laurie Little, Vice President - Investor Relations | ||
| Christina Ackermann, Executive Vice President General Counsel | ||
| Katharine Stevenson, Independent Director | ||
| Paul Boyatzis, Non-Executive Chairman of the Board | ||
| Ronald Farmer, Independent Director | ||
| Thomas Ross, Independent Director | ||
| Laizer Kornwasser, Executive VP and Company Group Chairman | ||
| Joseph Papa, Chairman of the Board, CEO | ||
| Ari Kellen, Executive VP and Company Group Chairman | ||
| John Geary, Company Secretary | ||
| Elif McDonald, Director, Investor Relations | ||
| Robert ChaiOnn, Executive Vice President General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director | ||
| John Paulson, Independent Director | ||
| Michael Pearson, Chairman, CEO and Director(Leave of absence) | ||
| Stephen Fraidin, Independent Director | ||
| Thomas Appio, Executive Vice President and Presidentident - Asia Pacific | ||
| Brian Stolz, Executive Vice President - Administration, Chief Human Capital Officer | ||
| Anne Whitaker, Executive Vice President | ||
| Russel Robertson, Independent Director |
Valeant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Valeant Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -21.51 | |||
| Return On Asset | 0.69 | |||
| Profit Margin | (10.65) % | |||
| Operating Margin | 5.01 % | |||
| Current Valuation | 32.38 B | |||
| Shares Outstanding | 349.3 M | |||
| Shares Owned By Insiders | 0.30 % | |||
| Shares Owned By Institutions | 51.10 % | |||
| Number Of Shares Shorted | 14.62 M | |||
| Price To Earning | 3.43 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Valeant Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Valeant Pharmaceuticals' short interest history, or implied volatility extrapolated from Valeant Pharmaceuticals options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Valeant Stock
If you are still planning to invest in Valeant Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Valeant Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |